Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All the Guidance They Need: Biosimilars Business Development Doesn't Wait For FDA

This article was originally published in RPM Report

Executive Summary

Wall Street is eagerly awaiting formal guidance from FDA on the new biosimilar pathway in the US. Biotech companies large and small aren't waiting.

You may also be interested in...

Biosimilars: Inverting the Innovator Development Model

When it comes to the new biosimilar pathway, it’s the IND—not the BLA—that matters.

Biogen Tests Biosimilars Waters In Joint Venture With Samsung

A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.

FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials

European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts